Prospective Evaluation of Fixation of the Prime Acetabular Cup

This is a prospective study to compare migration of the Microport Prime acetabular cup to a well-established acetabular cup design after total hip replacement. We will enroll 30 patients with the Prime cup and compare migration, function, pain and quality of life to a historical cohort of patients whom had a different cup used during surgery.

Study Overview

• Status: Withdrawn
• Conditions: Osteoarthritis, Hip
• Intervention / Treatment: Device: Prime Cup

Detailed Description

The gold standard for measurement of implant fixation over time is radiostereometric analysis (RSA). At the time of surgery, 0.8-1.0 mm Tantalum beads (typically n = 6-8 per region of interest) are inserted into the bone surrounding the implant of interest, and occasionally also into the polyethylene liner or insert of the implant. RSA exams are then acquired within the first 2 weeks post-operation, and again at 6 weeks, 3 months, 6 months, 1 year, and 2 years. Each exam involves a stereo x-ray acquisition with a calibration unit to reconstruct the 3D location of the implant relative to the marker beads. Across each exam, the migration of the implant relative to the marker beads is tracked compared to the baseline exam acquired within the first 2 weeks. RSA is extremely precise and accurate, and is able to track migrations on the order of 10's of microns. Large early migrations within the first 1-2 years post-operation are predictive of eventual implant loosening and failure. For acetabular cups, proximal migration of greater than 1.0 mm within the first 2 years post-operation is considered unacceptable, with cups migrating between 0.2 and 1.0 mm at risk of having a revision rate exceeding 5% at 10 years.

An RSA study should be completed for any new implant under the principles of phased innovation in orthopaedics. This ensures the new device will achieve long-term, stable fixation prior to its widespread adoption. Many device manufacturers incorporate the results of the RSA migration study into their marketing material. The advantage of RSA is its high degree of accuracy and its well-established thresholds for implant migration, meaning a relatively small number of patients are required to provide meaningful results.

Several joint replacement companies (Microport excluded) have previously released new products to the marketplace without RSA evaluation and these implants have later been identified as having ingrowth problems. The scientific aim of this study is to prove efficacy of ingrowth with a recently released implant.

This study design will be a prospective cohort with a retrospective control group. The study will be conducted at a single centre (London Health Sciences Centre - University Hospital, London, Ontario, Canada) with all cases performed by a single, fellowship-trained high-volume surgeon.

The study group will receive a Prime cementless acetabular cup (manufactured by Microport located in Arlington, Tennessee). All patients will also receive a cementless Profemur femoral stem with a 32 mm Cobalt Chromium femoral head, articulating on a highly crosslinked acetabular liner. The control group will be a previously published cohort that received the Reflection cementless acetabular cup with Roughcoat coating (Smith & Nephew, Memphis, TN). This is a well-established cup with long-term survivorship available in multiple registries, making it an ideal comparator.

Demographic details will be recorded from each patient. Outcome scores will be collected pre-operatively and at each post-operative visit. Standard outcome scores at our centre are the Western and McMaster Universities Osteoarthritis Index (WOMAC), Short Form 12 (SF-12), and Harris Hip Score. At the time of surgery, n = 8 of 1.0 mm Tantalum beads will be inserted into the pelvis surrounding the acetabular cup. Patients will undergo post-operative supine RSA exams within 0-2 weeks (baseline exam) and at 6 weeks, 3 months, 6 months, 1 year, and 2 years, following standardized protocols. RSA exams will be conducted at Robarts with a member of the research team escorting participants over to Robarts for each required post-operative visit.

• Study Type: Interventional
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Matthew Teeter, PhD; Phone Number: 34957 519-685-8500; Email: matthew.teeter@lhsc.on.ca
• Study Contact Backup: Name: Lyndsay Somerville, PhD; Phone Number: 36645 519-685-8500; Email: Lyndsay.Somerville@lhsc.on.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• hip osteoarthritis
• scheduled for primary total hip arthroplasty
• ability to provide informed consent
• over the age of 18 years

Exclusion Criteria:

• prior arthroplasty on the indicated joint
• individuals who do not speak or understand English
• individuals with neuromuscular disorders or cognitive impairments
• individuals ho live >100km from our centre and/or are unlikely to return for multiple follow-up appointments

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Prime Cup; The study group will receive a Prime cementless acetabular cup (manufactured by Microport located in Arlington, Tennessee). All patients will also receive a cementless Profemur femoral stem with a 32 mm CoCr femoral head, articulating on a highly crosslinked acetabular liner.	Device: Prime Cup; Patients in this group will have the Prime cementless acetabular cup used during surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Implant Migration	Migration will include translations, rotations and maximum total point motion measured between the 3D CAD models of the cup and the bone bead segment using model-based RSA software	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Short Form 12	Patient-reported questionnaire to assess general health and quality of life. Physical and Mental Health Composite Scores (PCS & MCS) are computed using the scores of twelve questions and range from 0 to 100, where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.	2 years
Western Ontario and McMaster Universities Osteoarthritis Index	Patient-reported questionnaire to assess function, stiffness and pain caused by hip or knee osteoarthritis. It is a self-administered questionnaire consisting of 24 items divided into 3 subscales (function, stiffness and pain). The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. The total score is calculated by summing the scores for each subscale. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.	2 years
Harris Hip Score	The Harris Hip Scale (HHS) was developed for the assessment of the results of hip surgery, and is intended to evaluate various hip disabilities and methods of treatment in an adult population. It is a physician-completed instrument that consists of subscales for pain severity (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 0-4 points), and range of motion (2 items, 0-5 points). The HHS is a measure of dysfunction so the higher the score, the better the outcome for the individual. The maximum score possible is 100.	2 years

Collaborators and Investigators

• Sponsor: Lawson Health Research Institute
• Collaborators: University of Western Ontario, Canada

Publications and helpful links

General Publications

• Valstar ER, Gill R, Ryd L, Flivik G, Borlin N, Karrholm J. Guidelines for standardization of radiostereometry (RSA) of implants. Acta Orthop. 2005 Aug;76(4):563-72. doi: 10.1080/17453670510041574.
• Malchau H, Bragdon CR, Muratoglu OK. The stepwise introduction of innovation into orthopedic surgery: the next level of dilemmas. J Arthroplasty. 2011 Sep;26(6):825-31. doi: 10.1016/j.arth.2010.08.007. Epub 2010 Oct 2.
• Pijls BG, Nieuwenhuijse MJ, Fiocco M, Plevier JW, Middeldorp S, Nelissen RG, Valstar ER. Early proximal migration of cups is associated with late revision in THA: a systematic review and meta-analysis of 26 RSA studies and 49 survivalstudies. Acta Orthop. 2012 Dec;83(6):583-91. doi: 10.3109/17453674.2012.745353. Epub 2012 Nov 5.
• Naudie DD, Somerville L, Korczak A, Yuan X, McCalden RW, Holdsworth D, Bourne RB. A randomized trial comparing acetabular component fixation of two porous ingrowth surfaces using RSA. J Arthroplasty. 2013 Sep;28(8 Suppl):48-52. doi: 10.1016/j.arth.2013.06.041. Epub 2013 Aug 13.

Study record dates

Study Major Dates

• Study Start (Anticipated): August 1, 2019
• Primary Completion (Anticipated): August 1, 2022
• Study Completion (Anticipated): August 1, 2022

Study Registration Dates

• First Submitted: July 29, 2019
• First Submitted That Met QC Criteria: July 29, 2019
• First Posted (Actual): July 31, 2019

Study Record Updates

• Last Update Posted (Actual): March 15, 2023
• Last Update Submitted That Met QC Criteria: March 12, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Keywords: arthroplasty; total hip replacement; radiostereometric analysis; implant migration
• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Osteoarthritis; Osteoarthritis, Hip
• Other Study ID Numbers: 113456

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: There is currently no plan to share individual participant data.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No